Differentiation between cancerous and normal hyperplastic lobules in breast lesions
Determining the risk that a particular area of hyperplastic breast tissue will progress to cancer is difficult and is currently expressed only as a general risk factor within the population. Using an antibody against the apoptotic purinergic receptor P2X7, we examined 40 cases each of the following...
Gespeichert in:
Veröffentlicht in: | Breast cancer research and treatment 2004, Vol.83 (1), p.1-10 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 10 |
---|---|
container_issue | 1 |
container_start_page | 1 |
container_title | Breast cancer research and treatment |
container_volume | 83 |
creator | SLATER, Michael DANIELETTO, Suzanne POOLEY, Margaret LIEW CHENG TEH GIDLEY-BAIRD, Angus BARDEN, Julian A |
description | Determining the risk that a particular area of hyperplastic breast tissue will progress to cancer is difficult and is currently expressed only as a general risk factor within the population. Using an antibody against the apoptotic purinergic receptor P2X7, we examined 40 cases each of the following histological categories: normal, moderate, florid and atypical hyperplasia, lobular carcinoma in situ, ductal carcinoma in situ, invasive lobular and invasive ductal carcinoma. These were previously diagnosed by H&E and supplied by clinical laboratories as tissue sections. Normal and mildly hyperplastic epithelium was devoid of the cytolytic P2X7 receptors whereas all epithelial cells in all cases of in situ or invasive lobular or ductal carcinoma labelled intensely. The lobular and ductal in situ cases labelled intracellularly while the invasive epithelial cancer cells showed intense cell surface label indicating an attempt was being made to induce apoptosis. All these receptors however are non-functional and thus unable to induce apoptosis. Approximately 10% of all hyperplastic lobules examined in the biopsied tissue, regardless of H&E classification, labelled for P2X7, which is suggestive of early metabolic cancerous change. The acini within lobules were either completely labelled with P2X7 or were completely devoid of the receptor. A potential advantage of this method lies in identifying early cancerous change in hyperplastic lobules and in establishing the true extent of cancerous spread in infiltrating lesions, thus facilitating the task of reporting clear surgical margins. |
doi_str_mv | 10.1023/b:brea.0000010670.85915.0f |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71701067</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>546093491</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-83b5f4ab28b74d647d9476b3e4a60e5812bcad955fae218575536091fbab7bc43</originalsourceid><addsrcrecordid>eNpdkFtLwzAYhoMobk7_gpSB3nUmTdK0u9vmPMBA8HAdkvYLdvRk0iL792ZbYWBuksDzvd_Lg9CU4BnBEX3Qc21BzfD-EBwLPEt4SvgMmzM0JlzQUEREnKMxJrEI4wTHI3Tl3NbjqcDpJRoRlvoXS8fo47EwBizUXaG6oqkDDd0vQB1kqs7ANr0LVJ0HdWMrVQbfuxZsWyrXFVlQNrovwQWFH_J9XBf4n49w1-jCqNLBzXBP0NfT-nP1Em7enl9Xi02YMZp0YUI1N0zpKNGC5TETecpErCkwFWPgCYl0pvKUc6MgIgkXnNMYp8RopYX2GRN0f8xtbfPTg-tkVbgMylLV4ItLQcTBjwen_8Bt09vad5MRiZhvw_Zp8yOU2cY5C0a2tqiU3UmC5d67XMrl-3ohT97lwbvExg_fDht6XUF-Gh1Ee-BuAJTLVGms11u4E8cZpYwK-gde4I0m</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>212443844</pqid></control><display><type>article</type><title>Differentiation between cancerous and normal hyperplastic lobules in breast lesions</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>SLATER, Michael ; DANIELETTO, Suzanne ; POOLEY, Margaret ; LIEW CHENG TEH ; GIDLEY-BAIRD, Angus ; BARDEN, Julian A</creator><creatorcontrib>SLATER, Michael ; DANIELETTO, Suzanne ; POOLEY, Margaret ; LIEW CHENG TEH ; GIDLEY-BAIRD, Angus ; BARDEN, Julian A</creatorcontrib><description>Determining the risk that a particular area of hyperplastic breast tissue will progress to cancer is difficult and is currently expressed only as a general risk factor within the population. Using an antibody against the apoptotic purinergic receptor P2X7, we examined 40 cases each of the following histological categories: normal, moderate, florid and atypical hyperplasia, lobular carcinoma in situ, ductal carcinoma in situ, invasive lobular and invasive ductal carcinoma. These were previously diagnosed by H&E and supplied by clinical laboratories as tissue sections. Normal and mildly hyperplastic epithelium was devoid of the cytolytic P2X7 receptors whereas all epithelial cells in all cases of in situ or invasive lobular or ductal carcinoma labelled intensely. The lobular and ductal in situ cases labelled intracellularly while the invasive epithelial cancer cells showed intense cell surface label indicating an attempt was being made to induce apoptosis. All these receptors however are non-functional and thus unable to induce apoptosis. Approximately 10% of all hyperplastic lobules examined in the biopsied tissue, regardless of H&E classification, labelled for P2X7, which is suggestive of early metabolic cancerous change. The acini within lobules were either completely labelled with P2X7 or were completely devoid of the receptor. A potential advantage of this method lies in identifying early cancerous change in hyperplastic lobules and in establishing the true extent of cancerous spread in infiltrating lesions, thus facilitating the task of reporting clear surgical margins.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1023/b:brea.0000010670.85915.0f</identifier><identifier>PMID: 14997049</identifier><identifier>CODEN: BCTRD6</identifier><language>eng</language><publisher>Dordrecht: Springer</publisher><subject>Biological and medical sciences ; Breast - metabolism ; Breast - pathology ; Breast cancer ; Breast Neoplasms - metabolism ; Breast Neoplasms - pathology ; Cancer research ; Carcinoma, Ductal, Breast - metabolism ; Carcinoma, Ductal, Breast - pathology ; Carcinoma, Intraductal, Noninfiltrating - metabolism ; Carcinoma, Intraductal, Noninfiltrating - pathology ; Carcinoma, Lobular - metabolism ; Carcinoma, Lobular - pathology ; Female ; Fibrocystic Breast Disease - metabolism ; Fibrocystic Breast Disease - pathology ; Gynecology. Andrology. Obstetrics ; Humans ; Immunohistochemistry - methods ; Mammary gland diseases ; Medical research ; Medical sciences ; Medical treatment ; Precancerous Conditions - metabolism ; Precancerous Conditions - pathology ; Predictive Value of Tests ; Receptors, Purinergic P2 - metabolism ; Receptors, Purinergic P2X7 ; Tumors</subject><ispartof>Breast cancer research and treatment, 2004, Vol.83 (1), p.1-10</ispartof><rights>2004 INIST-CNRS</rights><rights>Copyright Kluwer Academic Publishers Jan 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-83b5f4ab28b74d647d9476b3e4a60e5812bcad955fae218575536091fbab7bc43</citedby><cites>FETCH-LOGICAL-c438t-83b5f4ab28b74d647d9476b3e4a60e5812bcad955fae218575536091fbab7bc43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15433437$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14997049$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SLATER, Michael</creatorcontrib><creatorcontrib>DANIELETTO, Suzanne</creatorcontrib><creatorcontrib>POOLEY, Margaret</creatorcontrib><creatorcontrib>LIEW CHENG TEH</creatorcontrib><creatorcontrib>GIDLEY-BAIRD, Angus</creatorcontrib><creatorcontrib>BARDEN, Julian A</creatorcontrib><title>Differentiation between cancerous and normal hyperplastic lobules in breast lesions</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><description>Determining the risk that a particular area of hyperplastic breast tissue will progress to cancer is difficult and is currently expressed only as a general risk factor within the population. Using an antibody against the apoptotic purinergic receptor P2X7, we examined 40 cases each of the following histological categories: normal, moderate, florid and atypical hyperplasia, lobular carcinoma in situ, ductal carcinoma in situ, invasive lobular and invasive ductal carcinoma. These were previously diagnosed by H&E and supplied by clinical laboratories as tissue sections. Normal and mildly hyperplastic epithelium was devoid of the cytolytic P2X7 receptors whereas all epithelial cells in all cases of in situ or invasive lobular or ductal carcinoma labelled intensely. The lobular and ductal in situ cases labelled intracellularly while the invasive epithelial cancer cells showed intense cell surface label indicating an attempt was being made to induce apoptosis. All these receptors however are non-functional and thus unable to induce apoptosis. Approximately 10% of all hyperplastic lobules examined in the biopsied tissue, regardless of H&E classification, labelled for P2X7, which is suggestive of early metabolic cancerous change. The acini within lobules were either completely labelled with P2X7 or were completely devoid of the receptor. A potential advantage of this method lies in identifying early cancerous change in hyperplastic lobules and in establishing the true extent of cancerous spread in infiltrating lesions, thus facilitating the task of reporting clear surgical margins.</description><subject>Biological and medical sciences</subject><subject>Breast - metabolism</subject><subject>Breast - pathology</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - pathology</subject><subject>Cancer research</subject><subject>Carcinoma, Ductal, Breast - metabolism</subject><subject>Carcinoma, Ductal, Breast - pathology</subject><subject>Carcinoma, Intraductal, Noninfiltrating - metabolism</subject><subject>Carcinoma, Intraductal, Noninfiltrating - pathology</subject><subject>Carcinoma, Lobular - metabolism</subject><subject>Carcinoma, Lobular - pathology</subject><subject>Female</subject><subject>Fibrocystic Breast Disease - metabolism</subject><subject>Fibrocystic Breast Disease - pathology</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Immunohistochemistry - methods</subject><subject>Mammary gland diseases</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Medical treatment</subject><subject>Precancerous Conditions - metabolism</subject><subject>Precancerous Conditions - pathology</subject><subject>Predictive Value of Tests</subject><subject>Receptors, Purinergic P2 - metabolism</subject><subject>Receptors, Purinergic P2X7</subject><subject>Tumors</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkFtLwzAYhoMobk7_gpSB3nUmTdK0u9vmPMBA8HAdkvYLdvRk0iL792ZbYWBuksDzvd_Lg9CU4BnBEX3Qc21BzfD-EBwLPEt4SvgMmzM0JlzQUEREnKMxJrEI4wTHI3Tl3NbjqcDpJRoRlvoXS8fo47EwBizUXaG6oqkDDd0vQB1kqs7ANr0LVJ0HdWMrVQbfuxZsWyrXFVlQNrovwQWFH_J9XBf4n49w1-jCqNLBzXBP0NfT-nP1Em7enl9Xi02YMZp0YUI1N0zpKNGC5TETecpErCkwFWPgCYl0pvKUc6MgIgkXnNMYp8RopYX2GRN0f8xtbfPTg-tkVbgMylLV4ItLQcTBjwen_8Bt09vad5MRiZhvw_Zp8yOU2cY5C0a2tqiU3UmC5d67XMrl-3ohT97lwbvExg_fDht6XUF-Gh1Ee-BuAJTLVGms11u4E8cZpYwK-gde4I0m</recordid><startdate>2004</startdate><enddate>2004</enddate><creator>SLATER, Michael</creator><creator>DANIELETTO, Suzanne</creator><creator>POOLEY, Margaret</creator><creator>LIEW CHENG TEH</creator><creator>GIDLEY-BAIRD, Angus</creator><creator>BARDEN, Julian A</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>2004</creationdate><title>Differentiation between cancerous and normal hyperplastic lobules in breast lesions</title><author>SLATER, Michael ; DANIELETTO, Suzanne ; POOLEY, Margaret ; LIEW CHENG TEH ; GIDLEY-BAIRD, Angus ; BARDEN, Julian A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-83b5f4ab28b74d647d9476b3e4a60e5812bcad955fae218575536091fbab7bc43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Biological and medical sciences</topic><topic>Breast - metabolism</topic><topic>Breast - pathology</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - pathology</topic><topic>Cancer research</topic><topic>Carcinoma, Ductal, Breast - metabolism</topic><topic>Carcinoma, Ductal, Breast - pathology</topic><topic>Carcinoma, Intraductal, Noninfiltrating - metabolism</topic><topic>Carcinoma, Intraductal, Noninfiltrating - pathology</topic><topic>Carcinoma, Lobular - metabolism</topic><topic>Carcinoma, Lobular - pathology</topic><topic>Female</topic><topic>Fibrocystic Breast Disease - metabolism</topic><topic>Fibrocystic Breast Disease - pathology</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Immunohistochemistry - methods</topic><topic>Mammary gland diseases</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Medical treatment</topic><topic>Precancerous Conditions - metabolism</topic><topic>Precancerous Conditions - pathology</topic><topic>Predictive Value of Tests</topic><topic>Receptors, Purinergic P2 - metabolism</topic><topic>Receptors, Purinergic P2X7</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SLATER, Michael</creatorcontrib><creatorcontrib>DANIELETTO, Suzanne</creatorcontrib><creatorcontrib>POOLEY, Margaret</creatorcontrib><creatorcontrib>LIEW CHENG TEH</creatorcontrib><creatorcontrib>GIDLEY-BAIRD, Angus</creatorcontrib><creatorcontrib>BARDEN, Julian A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SLATER, Michael</au><au>DANIELETTO, Suzanne</au><au>POOLEY, Margaret</au><au>LIEW CHENG TEH</au><au>GIDLEY-BAIRD, Angus</au><au>BARDEN, Julian A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Differentiation between cancerous and normal hyperplastic lobules in breast lesions</atitle><jtitle>Breast cancer research and treatment</jtitle><addtitle>Breast Cancer Res Treat</addtitle><date>2004</date><risdate>2004</risdate><volume>83</volume><issue>1</issue><spage>1</spage><epage>10</epage><pages>1-10</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><coden>BCTRD6</coden><abstract>Determining the risk that a particular area of hyperplastic breast tissue will progress to cancer is difficult and is currently expressed only as a general risk factor within the population. Using an antibody against the apoptotic purinergic receptor P2X7, we examined 40 cases each of the following histological categories: normal, moderate, florid and atypical hyperplasia, lobular carcinoma in situ, ductal carcinoma in situ, invasive lobular and invasive ductal carcinoma. These were previously diagnosed by H&E and supplied by clinical laboratories as tissue sections. Normal and mildly hyperplastic epithelium was devoid of the cytolytic P2X7 receptors whereas all epithelial cells in all cases of in situ or invasive lobular or ductal carcinoma labelled intensely. The lobular and ductal in situ cases labelled intracellularly while the invasive epithelial cancer cells showed intense cell surface label indicating an attempt was being made to induce apoptosis. All these receptors however are non-functional and thus unable to induce apoptosis. Approximately 10% of all hyperplastic lobules examined in the biopsied tissue, regardless of H&E classification, labelled for P2X7, which is suggestive of early metabolic cancerous change. The acini within lobules were either completely labelled with P2X7 or were completely devoid of the receptor. A potential advantage of this method lies in identifying early cancerous change in hyperplastic lobules and in establishing the true extent of cancerous spread in infiltrating lesions, thus facilitating the task of reporting clear surgical margins.</abstract><cop>Dordrecht</cop><pub>Springer</pub><pmid>14997049</pmid><doi>10.1023/b:brea.0000010670.85915.0f</doi><tpages>10</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0167-6806 |
ispartof | Breast cancer research and treatment, 2004, Vol.83 (1), p.1-10 |
issn | 0167-6806 1573-7217 |
language | eng |
recordid | cdi_proquest_miscellaneous_71701067 |
source | MEDLINE; Springer Nature - Complete Springer Journals |
subjects | Biological and medical sciences Breast - metabolism Breast - pathology Breast cancer Breast Neoplasms - metabolism Breast Neoplasms - pathology Cancer research Carcinoma, Ductal, Breast - metabolism Carcinoma, Ductal, Breast - pathology Carcinoma, Intraductal, Noninfiltrating - metabolism Carcinoma, Intraductal, Noninfiltrating - pathology Carcinoma, Lobular - metabolism Carcinoma, Lobular - pathology Female Fibrocystic Breast Disease - metabolism Fibrocystic Breast Disease - pathology Gynecology. Andrology. Obstetrics Humans Immunohistochemistry - methods Mammary gland diseases Medical research Medical sciences Medical treatment Precancerous Conditions - metabolism Precancerous Conditions - pathology Predictive Value of Tests Receptors, Purinergic P2 - metabolism Receptors, Purinergic P2X7 Tumors |
title | Differentiation between cancerous and normal hyperplastic lobules in breast lesions |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T01%3A45%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Differentiation%20between%20cancerous%20and%20normal%20hyperplastic%20lobules%20in%20breast%20lesions&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=SLATER,%20Michael&rft.date=2004&rft.volume=83&rft.issue=1&rft.spage=1&rft.epage=10&rft.pages=1-10&rft.issn=0167-6806&rft.eissn=1573-7217&rft.coden=BCTRD6&rft_id=info:doi/10.1023/b:brea.0000010670.85915.0f&rft_dat=%3Cproquest_cross%3E546093491%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=212443844&rft_id=info:pmid/14997049&rfr_iscdi=true |